Novartis (NVS) is in advanced talks to acquire MorphoSys (MOR), a developer of cancer treatments that has a market value of $1.7B, two people familiar with the matter told Reuters’ David Carnevali. Novartis has so far prevailed over rival drug maker Incyte Corp (INCY), which also made an offer for MorphoSys, said the sources, who added that there is no certainty that the deal negotiations will conclude successfully, the report added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MOR: